Protagonist Therapeutics, Inc Income Tax Credits and Adjustments
Protagonist Therapeutics, Inc (PTGX) reported Income Tax Credits and Adjustments of $1.44 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-03-15.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxCreditsAndAdjustments · last filed 2023-03-15
- Protagonist Therapeutics, Inc income tax credits and adjustments for the quarter ending 2020-12-31 was $34.00K, a 95.60% decline year-over-year.
- Protagonist Therapeutics, Inc income tax credits and adjustments for the quarter ending 2020-09-30 was -$8.00K.
- Protagonist Therapeutics, Inc income tax credits and adjustments for the quarter ending 2020-06-30 was $1.23M.
- Protagonist Therapeutics, Inc income tax credits and adjustments for the quarter ending 2020-03-31 was $183.00K, a 1.67% increase year-over-year.
- Protagonist Therapeutics, Inc income tax credits and adjustments for fiscal 2020 was $1.44M.
- Protagonist Therapeutics, Inc income tax credits and adjustments for fiscal 2019 was -$775.00K.
- Protagonist Therapeutics, Inc income tax credits and adjustments for fiscal 2018 was -$658.00K.
| Period end | Income Tax Credits and Adjustments 3 month | Income Tax Credits and Adjustments 6 month | Income Tax Credits and Adjustments 9 month | Income Tax Credits and Adjustments 12 month |
|---|---|---|---|---|
| 2020-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $26.00K derived: sum of 2 quarters · filed 2023-03-15 | $1.25M derived: sum of 3 quarters · filed 2023-03-15 | $1.44M 10-K · filed 2023-03-15 |
| 2020-09-30 | -$8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $1.22M derived: sum of 2 quarters · filed 2021-11-03 | $1.40M 10-Q · filed 2021-11-03 | $2.18M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $1.41M 10-Q · filed 2021-08-04 | $2.19M derived: sum of 3 quarters · filed 2022-02-28 | $2.08M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $183.00K 10-Q · filed 2021-05-04 | $956.00K derived: sum of 2 quarters · filed 2022-02-28 | $854.00K derived: sum of 3 quarters · filed 2022-02-28 | -$772.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $773.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $671.00K derived: sum of 2 quarters · filed 2022-02-28 | -$955.00K derived: sum of 3 quarters · filed 2022-02-28 | -$775.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | -$102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$1.73M derived: sum of 2 quarters · filed 2020-11-04 | -$1.55M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | -$1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$1.45M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $180.00K 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | -$658.00K 10-K · filed 2021-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |